With the support of the National Institute on Drug Abuse, scientists at Wake Forest School of Medicine have been working to find a safe, non-addictive pain killer to help fight the current opioid crisis in this country.
And they may have done just that, though in an animal model.
Known as AT-121, the new chemical compound has dual therapeutic action that suppressed the addictive effects of opioids and produced morphine-like analgesic effects in non-human primates.
“In our study, we found AT-121 to be safe and non-addictive, as well as an effective pain medication,” said Mei-Chuan Ko, Ph.D., professor of physiology and pharmacology at the School of Medicine, part of Wake Forest Baptist Medical Center.
“In addition, this compound also was effective at blocking abuse potential of prescription opioids, much like buprenorphine does for heroin, so we hope it could be used to treat pain and opioid abuse.”
The findings are published in the Aug. 29 issue of the journal Science Translational Medicine.
The main objective of this study was to design and test a chemical compound that would work on both the mu opioid receptor, the main component in the most effective prescription pain killers, and the nociceptin receptor, which opposes or blocks the abuse and dependence-related side effects of mu-targeted opioids. Current opioid pain drugs, such as fentanyl and oxycodone, work only on the mu opioid receptor, which also produces unwanted side effects – respiratory depression, abuse potential, increased sensitivity to pain and physical dependence.
“We developed AT-121 that combines both activities in an appropriate balance in one single molecule, which we think is a better pharmaceutical strategy than to have two drugs to be used in combination,” Ko said.
In the study, the researchers observed that AT-121 showed the same level of pain relief as an opioid, but at a 100-times lower dose than morphine. At that dose, it also blunted the addictive effects of oxycodone, a commonly abused prescription drug.
The bifunctional profile of AT-121 not only gave effective pain relief without abuse potential, it also lacked other opioid side-effects that patients typically struggle with, such as itch, respiratory depression, tolerance and dependence.
“Our data shows that targeting the nociceptin opioid receptor not only dialed down the addictive and other side-effects, it provided effective pain relief,” Ko said. “The fact that this data was in nonhuman primates, a closely related species to humans, was also significant because it showed that compounds, such as AT-121, have the translational potential to be a viable opioid alternative or replacement for prescription opioids.”
Next steps include conducting additional preclinical studies to collect more safety data, and then if all goes well, applying to the Food and Drug Administration for approval to begin clinical trials in people, Ko said.
The Latest on: Non-addictive pain killer
via Google News
The Latest on: Non-addictive pain killer
- Olivia Palermo wears her stylish green coat over a chic all-black ensemble as she takes a walkon October 8, 2020 at 8:03 pm
And Olivia Palermo was parading the same chic fashions while out for a stroll in Brooklyn, New York on Thursday, wrapped up in the chic green checked coat she was seen in ... midi skirt looked to be ...
- Industrial Coatings Market Size to Hit US$ 107.32 Bn by 2027on October 8, 2020 at 3:14 pm
The global industrial coatings market was valued at USD 80.87 billion in 2019 and expected to reach over USD 107.32 billion by 2027 with register a compound annual growth rate (CAGR) of around 3.02% ...
- FERC study finds no risk from protective coating of Mountain Valley Pipelineon October 8, 2020 at 3:00 pm
Segments of steel pipe stockpiled along the path of a natural gas pipeline, exposed to the elements for two years while lawsuits delayed construction, pose no risk to the surrounding ...
- Ceramic Coating for Thermal Sprays Market to reach USD 2.81 billion by 2024, A&A Coatings and APS Materials Inc. emerge as Keyon October 8, 2020 at 2:17 pm
Before it's here, it's on the Bloomberg Terminal.
- Enterprise Ventures Corporation Receives Initial $2.1 Million Order for Specialty Coatings for Military Applicationson October 8, 2020 at 8:24 am
Concurrent Technologies Corporation and Enterprise Ventures Corporation work hand-in-hand to optimize and produce advanced technologies. Johnstown, PA, Oct. 08, 2020 (GLOBE NEWSWIRE) -- Enterprise ...
- Apple Is Evaluating Scratch-Resistant Diamond Like Coatings On Gorilla Glasson October 7, 2020 at 4:47 pm
Apple is evaluating methods to strengthen further its display Gorilla Glass by coating them with diamonds. $3.4 billion was spent by smartphone owners in 2017 replacing broken screens, most of which ...
- State-of-the-Art Allegiant Stadium Kicks Off With PPG Coatingson October 7, 2020 at 9:03 am
PPG today announced that, with the debut of Allegiant Stadium on September 21 in prime time and in front of a national television audience on Monday Night Football, most of the venue’ s interior, ...
- Nouveau Monde and Forge Nano Sign a Collaboration Agreement for Advanced Coatings for Li-Ion Battery Anode Materialon October 6, 2020 at 1:15 am
Coating of Nouveau Monde’s spherical graphite represents the final and most advanced step in the value chain of battery anode material, ...
- Nouveau Monde and Forge Nano Sign a Collaboration Agreement for Advanced Coatings for Li-Ion ...on October 6, 2020 at 12:30 am
Forge Nano’s advanced coating technologies will enhance the performance of Nouveau Monde’s graphite as part of the Lithium-ion battery system. Production of high-performance coated graphite anode ...
- Mitsui Chemicals Acquires Hydrophobic, Anti-Reflective Coatings Maker COTECⓇon October 5, 2020 at 9:34 pm
Mitsui Chemicals, Inc. (Tokyo: 4183; President & CEO: HASHIMOTO Osamu) today announced that group company SDC Technologies, Inc. has acquired COTECⓇ GmbH. Engaged in the manufacture, sale and research ...
via Bing News